Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00797966 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
A Phase 2 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 2
- Development phase
- 850
- Enrollment target
NCT00797966 is a Phase 2 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 850 participants.
The verdict
NCT00797966, a Phase 2 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 850 participants
- Enrollment target
Study Summary
Primary: To compare the efficacy of OPC-34712 to placebo as adjunctive treatment to an assigned open-label marketed antidepressant treatment (ADT)in patients who demonstrate an incomplete response to a prospective eight week trial of the same assigned open-label marketed ADT.
Interventions
- DRUG Placebo
- DRUG ADT
- DRUG OPC-34712
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 850 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00797966
The ClinicalTrials.gov registry entry for NCT00797966 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 850 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00797966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00797966 about?
NCT00797966 is a clinical study titled "Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder". Primary: To compare the efficacy of OPC-34712 to placebo as adjunctive treatment to an assigned open-label marketed antidepressant treatment (ADT)in patients who demonstrate an incomplete response to a prospective eight week trial of the same assigned open-label marketed ADT.
What is the current status of trial NCT00797966?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 850 participants. The study started on 2009-05. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00797966?
The interventions under investigation include: Placebo (DRUG), ADT (DRUG), OPC-34712 (DRUG).
Who is sponsoring clinical trial NCT00797966?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.